Nil

File No. FDC/IMP/19/000042
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(FDC Division)

Tele. No.:011-23236965
Fax No. :011-23236973

FDA Bhawan, Kotla Road
New Delhi-110002

Dated: 05 NOV 2020

To,

M/s. Otsuka Pharmaceuticals India Pvt. Ltd.,
Survey No. 199 to 201 & 208 to 210, Village-Vasana-Chacharwadi,
Tal: Sanand, Dist. Ahmedabad-382213.

Subject: **Permission to conduct Phase III clinical trial with the FDC of Amino Acid 3% + Glucose 7.5% with Electrolytes and Vitamin B1 injection (BFLUID) (1000ML Bag each) (Vide protocol no. OT-SS-IN-01, version no. 1.0, dated: 22.09.2020)-regarding.**

Dear Sir,

With reference to your online application submitted in Form CT-18 on dated 21.08.2019 please find enclosed herewith the "permission to conduct clinical trial study of new drug" bearing no. **CT-06-123/2020** under the provision of Drugs and Cosmetics Act and Rules. The permission is subject to the conditions mentioned below.

Kindly acknowledge receipt to this letter and its enclosures.

Yours faithfully,

(Dr. V. G. Somani)
Drugs Controller General (India)

CONDITIONS OF PERMISSION

I. Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;

II. Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

III. Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

IV. Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

V. In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

VI. The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

VII. Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

VIII. Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

IX. Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

X. Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;

XI. In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

XII. Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;

XIII. In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

XIV. In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

XV. The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

XVI. Where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

XVII. The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

XVIII. The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

XXXI. The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

XXXII. **The formulation intended to be used in the clinical trial study shall be manufactured under GMP conditions using validated procedures.**

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

Permission no.: CT-06-123/2020

1. The Central Licencing Authority hereby permits **M/s. Otsuka Pharmaceuticals India Pvt. Ltd.,Survey No. 199 to 201 & 208 to 210, Village-Vasana-Chacharwadi, Tal: Sanand, Dist. Ahmedabad-382213.** (Name and full address with contact details of the applicant) to conduct clinical trial of the new drug or investigational new drug as per protocol number **(Vide protocol no. OT-SS-IN-01, version no. 1.0, dated: 22.09.2020** in the below mentioned clinical trial sites.
2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].
3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: .....

Date: .....

Central Licencing Authority

Stamp

Dr. V. G. SOMANI
Drugs Controller General (India)
Dte. General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kotla Road, I.T.O.
New Delhi-110002

Annexure: 05 NOV 2020

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug:	Amino Acid 3% + Glucose 7.5% with Electrolytes and Vitamin B1 injection (BFLUID) (1000ML Bag each)
Therapeutic class:	Parenteral Nutrition
Dosage form:	Large Volume Parenteral
Composition:	1. **Upper chamber contains (500ml):** Acetyl cycteine JP 0.202g + Glycine JP 0.885g + L-AlanineUSP 1.200g + L-Arginine 1.575g + L-Aspartic acid BP 0.150g + L-Glutamic acid BP0.150g + L-Histidine USP 0.750g + L-Isoleucine JP 1.200g + L-Leucine JP2. 100g + L-Lysine Hydrochloride JP 1.965g + L-Methionine JP0.585g + L-Phenylalanine JP 1.050g + L-Proline USP 0.750g + L-Serine USP 0.450g + L-Threonine JP0.855g + L-Tryptophan JP 0.300g + L-Tyrosine USP 0.075g + L-Valine JP 1.200g + Dibasicpotassium Phosphate USP 0.501g + Dibasic Sodium Phosphate HydrateJP 0.771g + SodiumCitrate Hydrate JP0.285g + Sodium L-Lactate solution (60%) (as Sodium L-Lactate) USP 1.145g **Lower chamber contains (500ml):** Calcium Chloride Hydrate JP 0.184g + GlucoseUSP 37.499g + Magnesium Sulfate Hydrate JP 0.308g + Potassium chloride JP 0.317g + Thiamine Chloride Hydrochloride JP 0.96mg + Zinc sulphate Hydrate JP 0.70mg 2. **Upper chamber contains (1000ml):**

	Acetyl cycteine JP 0.404g + Glycine JP 1.770g + L-Alanine USP 2.400g + L-Arginine USP 3.150g + L-Aspartic acid BP 0.300g + L-Glutamic acid BP 0.300g + L-HistidineUSP 1.500g + L-Isoleucine JP 2.400g + L-Leucine JP 4.200g + L-Lysine Hydrochloride JP3.930g + L-Methionine JP1.170g + L-Phenylalanine JP 2.100g + L-Proline USP1.500g + L-Serine USP 0.900g + L-Threonine JP 1.710g + L-Tryptophan JP0.600g + L-Tyrosine USP 0.150g + L-Valine JP 2.400g + Dibasic potassium Phosphate USP 1.002g + Dibasic Sodium Phosphate Hydrate JP 1.542g + Sodium Citrate Hydrate JP 0.570g + Sodium L-Lactate solution (60%) (as Sodium L-Lactate) USP 2.290g **Lower chamber contains (1000ml):** Calcium Chloride Hydrate JP 0.368g + Glucose USP 74.998g + Magnesium Sulfate Hydrate JP 0.616g + Potassium chloride JP 0.634g + Thiamine Chloride Hydrochloride JP 1.920mg + Zinc sulphate Hydrate JP 1.400mg
Indications:	Provision of amino acid, electrolytes, vitamin B1, and water via a peripheral vein to patients with mild hypoproteinemia or mild malnutrition due to inadequate oral intake, and before and after gastrointestinal surgery.

Details of clinical trial site:

Names and address of clinical trial site:	As per annexure- A
Ethics committee details:	As per annexure- A
Name of principal investigator:	As per annexure- A

Annexure-A

Permission no.: CT-06-123/2020

S. No.	Name of PI	Site Name	Ethics Committee Name, Address & EC registration No
1	Dr K V V N Raju	Basavatarakam Indo American cancer hospital and Research Institute Road No 10, Banjara Hills, Hyderabad, Telangana - 500034, India	Institutional Ethics Committee Ethics Committee, Block 2, 3rd Floor, Basavatarakam Indo American Cancer Hospital & research institute, road no. 10, banjara hills, Hyderabad - 500034, Telangana India ECR/7/Inst/AP /2013/RR-20
2	Dr Amit Goyal	Sawai Maan Singh Medical College and Hospital J.L.N. Marg, Jaipur302004, Rajasthan	Ethics Committee of SMS Medical college & Attached Hospital, Office of EC, Second Floor, New administrative Block, SMS Medical college, JLN Marg, Jaipur, Rajasthan - 302004, ECR/26/Inst/Raj/2013/RR-19 (Institutional)
3	Dr Harshad Soni,	Kaizen Hospital, 132 Ft. Ring Road, Near Helmet Circle, Memnagar, Ahmadabad, Gujarat, India - 380052	Kaizen ethics Committee, Kaizen Hospital, 1st Floor, 132 Ft. Ring Road, Near Helmet Circle, Memnagar, Ahmedabad, Gujarat, India - 380052, ECR/447/Inst/ GJ/2013/RR19 (Institutional)
4	Dr Arunanshu Behera	PGIMER , Dept. of General Surgery , Nehru Hospital, Sector 12, Chandigarh, India - 160012	Institutional Ethics Committee, Post Graduate Institute of Medical Education and Research Room No. 6006, research Block A IEC Office, 6th Floor P N Chuttani Block Chandigarh - 160012, ECR/25/Inst/C H/2013/RR-20 (Institutional)
5	Dr B S Madhu,	K R Hospital, Mysore Medical College and RI, K R hospital, Mysore Medical College and Research Institute, Irwin Road, Mysore - 570001	IEC-MMC and RI and Associated Hospital, Mysore Medical College and Research Institute Irwin Road Mysore (Mysore) Karnataka - 570001 India, ECR/134/Inst/ KA/2013/RR19 (Institutional)
6	Dr M Gopichand	HCG City Cancer Centre, 33-25-33, Padavala revu, Gunadala , Vijayawada, Andhra Pradesh 520004	Institutional Ethics Committee - Hcg Curie CCC, HCG Curie City Cancer Centre 44-1-1/3 Padavalarevu, Gunadala Vijayawada Krishna Andhra Pradesh - 520004 India, ECR/869/Inst/ AP/2016/RR19 (Institutional)
7	Dr Anirban Nag,	Netaji Subhash Chandra Bose Cancer Hospital, 3081, Nayabad, New Gargia, Kolkata, West Bengal, 700094	Ethics Committee N S C B C Research Institute, Netaji Subhash Chandra Bose Cancer Hospital 3081 Nayabad New Garia Kolkata Kolkata West Bengal - 700094 India, ECR/286/Inst/ WB/2013/RR19 (Institutional)

8	Dr Rajnish Nagarkar ,	HCG Manavata Cancer Centre, Behind Shivang Auto, Mumbai Naka, Nashik Maharas htra - 422002, India	Manavata Clinical Research institute Ethics Committee, Behind Shivang Auto, Mumbai Naka, Nashik Maharashtra - 422002, India, ECR/500/Inst/ MH/2013/RR20 (Institutional)
9	Dr. AR Nitin Rao	M S Ramaiah Medical College and Hospitals , New BEL Road, MSRIT Post, Bangalore-560054	Ethics Committee, M S Ramaiah Medical College n Hospital M S Ramaiah Medical College and Hospitals M S Ramaiah Nagar MSRIT Post Bangalore Bengaluru (Bangalore) Urban Karnataka - 560054 India, ECR/215/Inst/ KA/2013/RR19 (Institutional)
10	Dr S. Thirunav Ukkarasu	Narayana Medical College and Hospital, Chinta Reddy Palem, Nellore, Andhra Pradesh, India - 524003	Ethics Committee Narayana Medical College Hospital, Narayana Medical College Chinthareddy Palem Muthukur Road Nellore Nellore Andhra Pradesh - 524003 India, ECR/460/Inst/ AP/2013/RR19
11	Dr Raxit Shah	Kailash Cancer Hospital & Research Centre, Kailash Cancer Hospital and Research Center Muni Seva Ashram, Goraj391760. Waghodia, Vadodara, Gujarat, India	IEC-KCHRC, I floor, Kailash cancer hospital and Research Center, Department of Clinical Research Goraj , Ta: Waghodia Vadodara Gujarat - 391760 India, ECR/49/Inst/G J/2013/RR-19
12	Dr Muralidhar	MNJ Hospital, MNJ institute of oncology and regional cancer center, Red hills Hyderabad 500004, Telangana India.	MNJ Institute of Oncology &regional Cancer Centre Ethics Committee , Ethics Committee MNJ Institute of Oncology & regional Cancer Centre, 3rd floor Room no 08, Red Hills, Hyderabad - 500004, Telangana India, ECR/227/Inst/ AP/2013/RR19 (Institutional)

Place: .....

Date: .....

05 NOV 2020

Central Licencing Authority

Stamp

Dr. V. G. SOMANI
Drugs Controller General (India)
Dte. General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kotla Road, I.T.O.
New Delhi-110002